Purchase this article with an account.
J.I. Calzada, B. Johnston, N. Gades, C. Rodriguez-Galindo, M. Wilson, B.G. Haik, C. Stewart; Topotecan Penetrates Rabbit Vitreous After Systemic Administration . Invest. Ophthalmol. Vis. Sci. 2003;44(13):4973.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose: Topotecan is an inhibitor of DNA topoisomerase I that may have a role in the treatment of advanced retinoblastoma. Its ocular pharmacokinetics have not been described. The purpose of this study was to evaluate the vitreal pharmacokinetics of intravenously injected topotecan Methods: New Zealand White rabbits were given intravenous infusions of 0.25 mg/kg Topotecan over 4 minutes. Serial vitreal samples were obtained through pars plana vitreal taps, with simultaneous blood sampling. Topotecan plasma and vitreous concentrations were measured using HPLC. Results: The plasma disposition of topotecan in rabbits was similar to that measured in other species with a plasma clearance of 9.2 L/h/m2 and terminal half life of 1.2 h. At the dosage administered, the area under the concentration-time curve (AUC0-6) was 88 ng/ml*h. The vitreal topotecan disposition showed a clearance of 30.9 L/h/m2 and a half life of 2.1 h. The AUC0-6 in the vitreous was 22 ng/ml*h. Based upon the ratio of vitreous to plasma AUC, topotecan penetration into the vitreous was approximately 40%. Conclusions: Our results indicate that topotecan has a relatively high penetration into the vitreous. To that effect, the rabbit is a good model to study vitreal pharmacokinetics of topotecan.
This PDF is available to Subscribers Only